1Operating loss was -$29.5 million, an 8.1% year-over-year improvement from -$32.1 million, as the company scaled back development spending while advancing its lead drug candidate.
2Net loss improved to -$26.6 million, a 27.7% year-over-year reduction from -$36.7 million, reflecting progress in managing overall expenses.
3Diluted EPS worsened to -$1.67, a -198.2% year-over-year decline from -$0.56, due to significant share count dilution from equity financings.
4Free cash flow was -$31.3 million, driven by cash used in operating activities of -$31.3 million and minimal capital expenditures of $24,000, indicating continued heavy investment in operations.
5Management expects continued losses and will require substantial additional capital to fund clinical trials and future commercialization efforts, as outlined in the company's risk factors.
6The company's operational focus remains on advancing its regulatory pathway and preparing for potential commercialization, with future plans contingent on securing necessary funding.